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Minimal residual disease (MRD) detection with
translocations and T-cell receptor and immunoglobu-
lin gene rearrangements in adult acute lymphoblastic
leukemia patients: a pilot study
Yetiﬂkin akut lenfoblastik lösemili hastalarda translokasyonlar ile T-hücre
reseptörleri ve immunglobulin yeniden yap›lanmalar›n› kullanarak minimal
rezidüel hastal›k tespiti
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Abstract
Objective: Monitoring minimal residual disease has become increasingly important in clinical practice of ALL management.
Break-point fusion regions of leukaemia related chromosomal aberrations and rearranged immunoglobulin (Ig) and T cell-
receptor (TCR) genes are used as leukaemia specific markers in genetic studies of MRD.
Material and Methods: A total of 31 consecutive patients with newly diagnosed ALL were screened for eligibility criteria. Of
those 26 were included in the study. One patient with partial response following induction therapy and four patients who were
lost to follow-up after induction were excluded from the study; thus 21 patients were evaluated for MRD by using polymerase
chain reaction (PCR), heteroduplex analysis, sequencing and quantitative real time PCR techniques. 
Results: Chromosomal aberrations were detected in 5 (24%) of the patients and were used for MRD monitoring. Three
patients had t(9;22) translocation, the other 2 had t(4;11) and t(1;19). MRD-based risk stratification of the16 patients analysed
for Ig/TCR rearrangements revealed 3 low-risk, 11 intermediate-risk and 2 high-risk patients.
Conclusion: MRD monitoring is progressively getting to be a more important predictive factor in adult ALL patients. As report-
ed by others confirmed by our limited data there is a good correlation between MRD status and clinical outcome in patients
receiving chemotherapy. The pilot-study presented here is the first that systematically and consecutively performs a molecu-
lar MRD monitoring of ALL patients in Turkey. (Turk J Hematol 2008; 25: 124-32)
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Özet
Amaç: Minimal rezidüel hastal›¤›n (MRH) takibi, ALL tedavisinin klinik uygulamalar›nda giderek önem kazanmaktad›r. Lösemide
s›kl›kla görülen kromozomal k›r›k noktalar› ve immunglobulin (Ig) ve T-hücre reseptörleri (THR), MRH takibinde lösemiye özgü
marker olarak kullan›lmaktad›r. 
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Acute lymphoblastic leukemia (ALL) is a heterogeneous
malignant disease of lymphoid hematopoietic precursor cells.
Complete remission (CR) rates of up to 95% can be achieved
with current treatment strategies in ALL. However, responses
are not durable and relapse is inevitable for most ALL patients,
resulting in long-term survival rates of only 30-35% [1-4].
Residual malignant cells that remain beyond the detection level
of standard cytomorphological diagnostic methods are held
responsible for the ultimately ensuing relapse. These cells 
represent the minimal residual disease (MRD). Thus, monitoring
MRD has become increasingly important in clinical practice of
ALL management. A large number of studies have shown that
MRD status in hematopoietic malignancies is a useful tool for
predicting clinical outcome [4]. Techniques for studying MRD
rely on the detection of a leukemia cell-specific marker that
enables distinguishing blasts from normal cells. Currently, two
methods are available: [1] genetic (molecular) studies and [2]
immunophenotyping. 
Break-point fusion regions of leukemia-related chromosomal
aberrations and rearranged immunoglobulin (Ig) and T–cell
receptor (TCR) genes, which can be detected by polymerase
chain reaction (PCR), are used as leukemia-specific markers in
genetic studies of MRD. Recurrent chromosomal aberrations are
detected in 30-40% of ALL cases [5]. The four most commonly
encountered chromosomal translocations are t(9;22), t(12;21),
t(4;11) and t(1;19). Newly developed real-time quantitative PCR
techniques are sensitive to detect one leukemic cell in104-106
normal cells [5]. 
The immune system encounters millions of different antigens
and antigenic epitopes. A limited number of gene segments are
able to code for the receptor diversity by the combinations of
gene segments, which are different in each lymphocyte or lym-
phocyte clone. During early differentiation of B- and T-cells, the
germ-line segments of variable (V), diversity (D) and joining (J)
genes in Ig and TCR gene complexes rearrange. Each lympho-
cyte gets a specific combination of V-(D)-J segments that codes
the variable domains of Ig or TCR molecules [6]. The random
insertion and deletion of nucleotides at the junction sites of V, (D),
and J gene segments turn the junctional regions of Ig and TCR
genes into fi gerprint-like sequences, which probably differ in
each lymphocyte and thus in each lymphoid malignancy.
Therefore, junctional regions can be used as leukemia-specific
markers in the analysis of MRD [7]. Such targets can be identi-
fied at initial diagnosis by various PCR primer sets in >95% of
patients with lymphoid malignancies [6,8]. Immunological MRD
tests include the flow-cytometric profiling of the leukemia-asso-
ciated aberrant immunophenotype [9,10]. Results from MRD
analysis based on flow-cytometric immunophenotyping were
found similar to those of molecular studies [11].
Several studies based on Ig/TCR gene rearrangements for
monitoring MRD have shown that the most important application
of MRD monitoring in ALL is to assess initial responses to 
cytotoxic therapy [12]. After the induction therapy, low amounts
or absence of MRD in bone marrow seem to predict outcome,
and the risk of relapse is proportional to the level of MRD [13,14].
Multivariate analysis showed that the level of MRD after induction
therapy is the most powerful prognostic factor, independent of
other clinically relevant risk factors, such as age, blast count,
immunophenotype, presence of chromosomal aberrations at
diagnosis, and response to prednisone [15]. The results from the
large prospective MRD study of the international BFM Study
Group showed that the information on the kinetics of the
decrease in tumor load after induction treatment and before
consolidation treatment is more useful than analyzing MRD at
one time point [13].
Accordingly, patients can be separated into three subgroups
as: 1 Low-risk patients (no MRD at both time points, 5-year
relapse rate of 2%); 2 high-risk patients (with intermediate 
10
-3 or high ≥10
-2 MRD at both time points, 5-year 
relapse rate of 80%); and 3 intermediate-risk patients 
(5-year relapse rate of 22%). 
Due to financial and technical constraints, molecular MRD
monitoring of ALL has been a “difficult-to-perform” task in
Turkey and is still not a routine laboratory procedure. 
The primary aim of this pilot study was to establish the 
molecular method of MRD monitoring in ALL and create the
required technical background for a central MRD follow-up in
Turkey. The secondary aim was to determine the impact of MRD
on clinical outcome of ALL. 
Material and Methods 
Patients
All patients referred to the Hematology Outpatient Clinic of
Cerrahpaﬂa Medical Faculty with the probable diagnosis of ALL
between March 2002 and December 2004 were screened for
Gereç ve Yöntemler: Yeni ALL tan›s› alm›ﬂ toplam 31 hasta çal›ﬂmaya al›nd›, kriterlere uygun 26 hasta ile çal›ﬂma
gerçekleﬂtirildi. 5 hasta çal›ﬂma sürecinde takip d›ﬂ› kald› ve 21 hasta polimeraz zincir reaksiyonu (PCR), heterodupleks anal-
izi, dizileme ve kantitatif “real time” PCR yöntemleri kullan›larak MRH aç›s›ndan de¤erlendirilmeye al›nd›. 
Bulgular: Bu hastalardan 5 (%24) tanesinde kromozomal translokasyonlar tespit edildi. 3 hastada t(9;22), 1 hastada t(4;11)
ve 1 hastada da t(1;19) translokasyonlar› belirlendi. MRH’a dayal› risk tespitinde 16 hasta Ig/THR yeniden yap›lanmalar› için
analiz edildi ve 3 tanesi düﬂük risk gurubu, 11 tanesi orta risk gurubu ve 2 tanesi de yüksek risk gurubuna dahil edildi.
Sonuç: Elde etti¤imiz sonuçlar, kemoterapi alan hastalarda klinik sonuçlar›n, MRH durumlar› ile iyi korelasyon gösterdi¤ini
desteklemektedir. Bu pilot çal›ﬂma ile ülkemizde ilk defa sistematik olarak tan› ve takip örneklerinde MRH takibi gerçekleﬂtiril-
miﬂtir. (Turk J Hematol 2008; 25: 124-32)
Anahtar kelimeler: MRH takibi, Ig/THR gen yeniden düzenlenmesi, ALL.
Geliﬂ tarihi: 19 Kas›m 2007 Kabul tarihi: 19 Haziran 2008
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mature B-ALL –L3) who were 15 years of age or older and had
adequate bone marrow samples for molecular MRD studying
were included in the study. Morphological and immunopheno-
typical diagnoses of ALL were made according to 
French-American-British (FAB) [16] and the European Group for
Immunological Classification of Acute Leukemia (EGIL) [17]
criteria, respectively. Only the patients who achieved 
morphological complete remission (mCR) following induction
therapy were evaluated for MRD monitoring. 
All patients were treated with the GMALL 93/05 
chemotherapy protocol [18]. Treatment consisted of an 
induction, reinduction, and consolidation therapy lasting one
year based on different combinations of the drugs 
methylprednisolone, cyclophosphamide, vincristine, daunoru-
bicin, methotrexate, asparaginase, cytosine arabinoside, 
6-mercaptopurine (6-MP), and etoposide (VP16). The 
maintenance therapy consisted of intermediary application of 
6-MP plus methotrexate for a total of two years. The 
combination, dosage and schedule of the chemotherapy 
differed for T-ALL, and standard- and high-risk B-ALL [19]. A
search for HLA-matched donor was initiated at first clinical/
morphological relapse. The study protocol allowed patients
aged less than 46 and with a good performance status to 
proceed to allogeneic bone marrow transplantation if they had
achieved a second mCR and had a fully-matched donor. 
Bone marrow samples for morphological, immunophenotyp-
ical and molecular analyses were collected from all patients at
initial diagnosis and then from those who achieved a post-induc-
tion CR at pre-defined time points (Days (D) 30, 90, 180, 270,
360) during the remainder of the therapy. Additional yearly MRD 
controls after D360 were done only for those patients who 
maintained mCR.
The treatment, clinical management, follow-up and
immunophenotyping of the patients as well as the 
morphological examination of bone marrow samples were done
in the Hematology and Pathology Departments of Cerrahpaﬂa
Medical Faculty, ‹stanbul University. Laboratory work of 
molecular MRD monitoring was performed in the Genetics
Department of the Institute for Experimental Medicine and
Research (DETAE), ‹stanbul University. 
Patients were also classified according to conventional and
MRD-based risk grouping systems (Tables 1, 2) [20].
The study was approved by the ethical committee of the
Cerrahpaﬂa Faculty of Medicine, ‹stanbul University, and
informed consents were obtained from all the participating
patients. 
Methods
The initial marrow samples were first analyzed for the 
presence of four unique chromosomal translocations, namely
t(4;11), t(9;22)-p190, t(9;22)-p210, t(12;21) and t(1;19). For this,
RNA was isolated by RNeasy isolation kit (Qiagen, GmbH
Germany). 1μg of RNA, 1U of MMLV reverse transcriptase and
random hexamer were used to synthesise cDNA. If the patient
was found positive for one of the above-mentioned 
translocations in the initial (D0) sample, then the MRD 
monitoring was done using this marker thereafter. 
If the patient was negative for all of the translocations, 
targeting PCRs were performed to find a patient-specific Ig/TCR
rearrangement (Figure 1). In brief, genomic DNA was extracted
from peripheral blood by using proteinase K/salting out method.
For each 50μl PCR reaction, 60 ng DNA sample, 6.3 pmol of the
primers, and 0.5 U Ampli Taq Gold polymerase (Applied
Biosystems, Foster City, CA, USA) were used. The sequences of
oligonucleotides used for amplification are given in Table 3. PCR
conditions were 10 min at 94°C, followed by 35 cycles of 45 sec
at 92°C, 90 sec at 60°C, and 2 min at 72°C, and last step of 10
min at 72°C (Applied Biosytems 9600). Positive and negative
controls were included in all experiments. 
PCR products had to be analyzed for their clonal origin to
confirm that they were derived from the malignant cells and not
from contaminating normal cells with similar Ig or TCR gene
rearrangements. For this, precise nucleotide sequences of the
junctional regions were determined. This sequence information
allowed the design of junctional region-specific oligonucleotides.
These oligonucleotides were then used to detect malignant cells
among normal lymphoid cells during follow-up of patients in two
different ways. First, oligonucleotides were utilized as 
patient-specific junctional region probes in hybridization 
experiments to detect PCR products derived from the malignant
cells. Second, the junctional region-specific oligonucleotides
were used as primers to specifically amplify the rearrangements
of the malignant clone.
To determine the clonality, PCR products were analyzed by
heteroduplex gel technique. The samples were denatured at
94°C for 5 min after the final cycle of amplification and 
subsequently cooled to 4°C for 60 min to induce duplex 
formation. Samples were then loaded immediately on 6% 
non-denaturing polyacrylamide gels in 0.5x tris-borate-EDTA
(TBE), ran at room temperature, and visualized by ethidium 
Table 1. Conventional risk stratification in adult ALL
G Go oo od d   ( (S St ta an nd da ar rd d) ) A Ad dv ve er rs se e   ( (H Hiig gh h) )
Age ≤ 50 years > 50 years
WBC ≤ 30000/μl > 30000/μl (in B-lineage)
≤ 100000/μl > 100000/μl (in T-lineage) 
Immunophenotype Thy ALL Pro B [B-lineage, CD10 (-)]
Early T (T-lin., CD1a -, sCD3-)
Mature T (T-lin., CD1a -, sCD3+)
Cytogenetics High hyperdiploidy
Molecular genetics Complex aberrations ) TEL-AML
t(9;22)/BCR-ABL
t(4;11)/ALL1-AF4
t(1;19)/PBX-E2A
Table 2.  MRD-based risk grouping in ALL
MRD risk group After Induction Post Consolidation
MRD low risk <10-4 and negative always < 10-4
MRD high risk > 10-4 or 2 times > 10-4 
MRD intermediate risk MRD evaluation not possible
Technical prerequisites not fulfilled
Inconclusive course of MRD 
Note: Technical prerequisites are: at least two clone specific markers with minimum sensi-
tivity of 10-4; material from decisive timepoints available
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background positive control, a buffy coat, representing five
healthy individuals, was used in each run. Monoclonal samples
were used for the direct sequencing. The two bands of the
biclonal samples were separated and removed from the 
polyacrylamide gel and the bands were sequenced separately. 
Direct sequencing of rearrangements was performed with
the specific primers using the dye-terminator cycle sequencing
kit on an ABI377 sequencer as previously described [21]. 
Vd2-Dd3 sequences were evaluated for the presence of the
common stems and segments, which were identified by 
comparison to germ-line sequences as previously described
[22,23]. For alignments of Dd2 and Dd3 segments in Vd2-Ja
junctional regions, at least five consecutive matching nucleotides
were required. VH, DH and JH segments were identified using
DNAPLOT software (W. Müller H-H. Althaus, University of
Cologne, Germany) by searching for homology with all known
human germ-line VH, DH and JH sequences obtained from the
VBASE directory of human Ig genes. Vg and Jg gene segments
were identified by comparison to germ-line gene TCRG
sequences.
Patient-specific primers were positioned at the 
junctional regions. A standard annealing temperature of 60°C
was used. To determine the efficacy of amplification and the
sensitivity of PCR target, D0 sample was diluted in 10-fold steps
into control steps from 10-1 down to 10-6. Serial dilutions of 
diagnostic samples were analyzed in duplicate. For the 
correction of quantity and quality of DNA, albumin gene was
used. Non-specific amplification was defined as any 
amplification observed in control DNA. The reproducible 
sensitivity of primers/probe combination was defined as the
maximal 10-fold dilution step with a maximal difference in cycle
threshold (CT) value of 1.5 between the duplicate of involved 
dilution samples and with a maximal CT value of 40 cycles.
Furthermore, the CT values of the reproducible sensitivity had to
be at least three cycles lower than the CT values of control DNA.
If non-specific amplification was not observed, maximal 
sensitivity was defined as the maximal 10-fold dilution of the
diagnostic sample giving specific but non-reproducible 
amplification. 
MRD levels were stated as the proportion of leukemic cells to
all nucleated cells in the sample. The aim was to obtain at least
two molecular markers per patient with a sensitivity of min 10-4.
PCR results were interpreted according to the common criteria
of the laboratories organized in the European Study Group on
MRD-Detection in ALL (ESG MRD-ALL; coordinator: J. J .M. van
Dongen, Rotterdam, The Netherlands).
Overall survival was estimated by using Kaplan-Meier
analyses.
Results
A total of 31 consecutive patients with newly diagnosed ALL
were screened for eligibility criteria. Of those, 26 were included
in the study. One patient with partial response following 
induction therapy and four patients who were lost to follow-up
after induction were excluded from the study; thus, 21 patients
were evaluated for MRD (Table 4). 
Mean age of the patients was 32 years (16-67). Of the 21
patients, 10 were female and 11 were male. Six patients (28%)
had T-cell ALL and 15 patients (72%) were diagnosed as B-cell
ALL. Mean leukocyte count and serum lactate dehydrogenase
(LDH) levels at diagnosis were 54700/mm3 (400-257000) and
1330 U/L (290-11754), respectively. 
P Pr riim me er r   c co od de e S Siiz ze e   o of f   p pr riim me er r   ( (b bp p) ) S Se eq qu ue en nc ce e   ( (5 5’ ’→ →3 3’ ’) )
V_4-2T 18 tgggatgggcagagcaat
V_.7-2T 21 tgtgctagcagcttccctgag
V_3-6B 23 gggtctattactgccgaaggact
Intron-6B 16 gctttccgcccggagt
V_2-9B 17 gacggcccgtagggtgt
V_2-9B 18 gtgacacctcccggtgct
V_12.4-10T 22 tagcgccaggggtactactacg
VH4.4-11B 21 gcgagaggtggtgttcatgt
VH3.33-11B 17 gcggtggggggtattgt
J_30-11B 21 gttcccatatcccccagtacc
V_2-12B 20 cacctgggacccgaattatt
VH3.7-12B 24 gtgtattactgtgcgttcctggac
D_3-14B 18 cgtatcccccatcggaag
VH3.7-14B 24 gatacagctatgtagccccggtac
J_29-14B 21 caagaggtgtgtttcccctgg
V_1.17-15B 23 cataatagttaccctcggcccta
VH3.23-15B 22 ccggggactgactacgattct
V_2.3-15B 21 gcacacaagtcttgtcggagc
D_2-24B 21 taacattgtggggaccaccat
Table 3. Oligonucleotide sequences used for amplification
Screening PCR
(Searching for the presence of known IgH/TCR gene regions)
Heteroduplex PCR
(Checking the clonality of the identified IgH/TCR gene fragments)
Sequencing
(Sequencing the clonal gene fragments- at least 2 clonal regions)
Formation of Primers
(Analysis and isolation of the clonal rearranged gene region in the sequenced frag-
ment and derivation of clone-specific primers)
Testing the Sensitivity of the Primers
(Sensitivity tested with RT-PCR in dilutions 10-1 to 10-6)
Quantifying the Clonal Markers in Follow-Up Samples
(Quantitative real-time [QRT]-PCR with DNA samples obtained from remission BM
using the clonal primers)
MRD Evaluation
(Detecting the MRD status by QRT-PCR and clinical output results)
F Fiig gu ur re e   1 1. . Flowchart of Ig/TCR rearrangement analysis
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P P A Ag ge e I IP P W WB BC C L LD DH H   ( (U U/ /L L) ) B Blla as st t   % % C CG G E EM MD D m mC CR R C CR RG G L La as st t   S St ta at tu us s
I I/ /S Se ex x c co ou un nt t   ( (/ /μ μll) ) ( (N N< <4 48 80 0) ) ( (B BM M/ /P P) )
N 31 T- 4300 290 30 (BM) (-) (-) (+) S Alive, in remission 
Y F ALL (63 months)
R 19 T- 51300 11754 99 (BM) (-) (-) (+) S Alive, in remission 
A M ALL (63 months)
S 21 cB- 600 342 98 (BM) (-) (-) (+) S Died (14 months)
U M ALL
O 28 B- 100000 3713 90 (P) t(1;19) (-) (+) H Died (3 months)
E M ALL
M 32 T- 58700 U 34 (P) (-) (-) (-) S Unknown*
T M ALL
H 56 cB- 7400 1329 36 (BM) (-) (+) (+) S Died (49 months)
K F ALL
Ö 67 cB- 70000 355 95 (BM) t(9;22) (-) (+) H Died (14 months)
Ö M ALL
H 32 T- 1300 900 41 (BM) (-) (-) (+) S Died (28 months)
A F ALL
G 22 B- 160000 2024 67 (BM) (-) (+) (+) H Died (14 months)
G M ALL
Ç 24 T- 24000 U 84 (BM) (-) (-) (+) S Died, in remission
Ö F ALL (5 months)
Y 16 B- 400 261 58 (BM) (-) (+) (+) S Died (33 months)
D M ALL
S 43 pB- 6400 2220 85 (BM) (-) (+) (+) H Died (22 months)
A F ALL
N 17 cB- 6100 223 96 (BM) (-) (-) (+) S Died (37 months)
A M ALL
B 21 B- 48000 738 80 (BM) t(9;22) (-) (+) H Died (14 months)
Ç F ALL
S 27 cB- 3000 2969 90 (BM) (-) (-) (+) S Alive, in remission
A M ALL (41 months) 
A 42 pB- 30000 639 71 (BM) (-) (-) (+) H Alive, in remission
Ç M ALL (41 months)
F 45 pB- 20400 U U (-) U U H Unknown*
Ç M ALL
A 16 cB- U U U (-) (+) (+) U Unknown*
Y M ALL
M 45 pB- 257000 700 71 (BM) t(4;11) (-) (+) H Died (16 months)
Ç F ALL
H 37 ppB- 4200 681 90 (BM) (-) (-) (+) H Died (5 months)
A F ALL
Z 74 cB- U U U (-) U U U Unknown*
C F ALL
S 22 T- 81000 1141 62 (BM) (-) (+) (+) S Alive, in remission
T M ALL (53 months)
Ö 16 cB- 2500 2489 70 (BM) (-) (-) (+) S Alive, in active disease
A F ALL (35 months)
ﬁ 46 pB- 37000 U U (-) (-) U H Unknown*
S F ALL
T 44 cB- 46500 2450 96 (BM) t(9;22) (-) (+) H Died (7 months)
E M ALL
A 41 T- 150000 2304 95 (BM) (-) (-) (+) H Died (6 months)
Y M ALL
PI: Patient initials, IP: Immunophenotype,  M: Male, F: Female,  WBC: White blood cell, EMD: Extramedullary disease, CRG: Conventional risk group, H: High risk, S: Standard risk, U: Unknown, 
P: Peripheral blood,  BM: Bone marrow,  LDH: Lactate dehydrogenase,  CG: Cytogenetics,  mCR: Presence of morphological complete remission following induction chemotherapy,  cB-ALL:  Common B-
cell ALL,  pB-ALL: ProB-cell ALL,  ppB-ALL: Pre-proB-cell ALL, *  Patients were not considered for MRD analysis due to lack of adequate clinical and laboratory data (see text for details)
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Three-year survival rate was 38%. At the time of the last 
evaluation (July 2007 [36 months after the completion of last
patient accrual]), six patients (29%) were alive. Five (3 T-ALL, 
1 common-B-ALL and 1 precursor B-ALL) out of those six
patients were still in CR with a median survival of 53 months and
one was in late relapse. None of the long-term survivors 
exhibited bad prognostic chromosomal aberrations. About 25%
of patients died within six months of diagnosis, following a 
post-induction CR, mainly due to infections and early relapse.
Only one patient died in remission (5%) as a result of 
treatment-related genitourinary infection. According to the 
prognostic criteria of the German Acute Lymphoblastic
Leukemia Group, 10 patients fulfilled the high-risk criteria,
whereas the remaining 11 were in the standard-risk group 
(Table 4). Median survival in the standard-risk group was 
37 months (5-63 months), with 7 of the 11 patients (63%) 
surviving more than three years. The median survival and the
three-year survival rate in the high-risk group were significantly
lower (14 months [3-41 months] and 10%, respectively).
Chromosomal aberrations were detected in 5 (24%) of the
patients and were used for MRD monitoring. Three patients had
t(9;22) translocation, and the other 2 had t(4;11) and t(1;19). By
definition, all of these patients were at high-risk. Median duration
of survival among these patients was 14 months (3-16 months)
(Table 5). 
Ig/TCR rearrangements were studied for the remaining 16
patients as MRD marker (Table 6). However, clonal Ig/TCR
rearrangements could only be detected in seven of those
patients. Since the number of patients was too low to do a 
statistical analysis, results were evaluated as case-based data:
-Patient RA had mCR and no detectable MRD at D30. His
MRD continued to be negative at the end of the third year. No
MRD was checked thereafter. The patient was still in mCR at the
time of the last follow-up (63 months after diagnosis), 
-Patient HK became MRD-negative by the end of the first
year of her diagnosis while she was still receiving the pre-main-
tenance chemotherapy. She remained MRD-negative until the
21st month of treatment (oral maintenance phase) when an
MRD of 6, E-05 was detected. Central nervous system (CNS)
and systemic relapse soon followed. No donor search was initi-
ated due to advanced age of the patient. She died of progres-
sive disease 25 months after the relapse despite having had sec-
ondary chemotherapy regimens with considerable success.
-Patient GG, although having achieved a morphological
remission after the induction chemotherapy, never became
MRD-negative and showed a morphological relapse in the 6th
month of therapy. He had no HLA-matched donor. He survived
for another eight months on salvage chemotherapy regimens
and died in sepsis 14 months after his diagnosis.
-Patient YD was a standard-risk patient who became 
MRD-negative just after the induction therapy and completed his
chemotherapy schedule preserving his MRD negativity for about
20 months. He relapsed in the third year and died due to 
infection after a total survival of 33 months. No HLA-matched
donor could be found.
-Patient SA never became MRD-negative but remained in
clinical/morphological remission while receiving chemotherapy.
Neither related nor unrelated HLA-matched donor was available.
She relapsed in the period between the last two consolidation
treatments. Thereafter, the patient was treated with a salvage
regimen that resulted in CNS involvement. She then refused any
kind of further chemotherapy and was followed with supportive
treatment until she died of infection and bleeding 22 months
after her diagnosis.
-Patient AC became MRD-negative within six months of
diagnosis while still receiving the pre-maintenance phase of
chemotherapy. No other MRD control could be done after 
the first year due to difficulties in follow-up. The patient 
was last seen in July 2007 (41 months after diagnosis), still in
complete morphological and clinical remission.
-Patient OA, despite becoming MRD-negative at the D30
evaluation, became positive within six months of diagnosis. She
remained in mCR while receiving consolidation chemotherapy.
She ultimately relapsed after 18 months of treatment while on
oral maintenance and survived on secondary chemotherapy 
regimens without achieving durable mCR. Thirty-five months
after diagnosis she was still alive with active disease and 
receiving palliative treatment. No HLA-matched donor could be
identified. 
MRD-based risk stratification of the 16 patients analyzed for
Ig/TCR rearrangements revealed 3 low-risk, 11 intermediate-risk
and 2 high-risk patients. The overall survival rates were 35, 37,
18 for the low-, intermediate- and high-risk groups, respectively
(Table 6).
GMALL 05/93 consists of a 52-week pre-maintenance
phase including induction, reinduction and consolidation
chemotherapies and an oral maintenance phase of two years.
Nine of the 21 patients (43%) including the six long-term 
survivors were able to complete the pre-maintenance phase of
the therapy. The median duration of treatment for this group was
100 weeks (almost twice as long as suggested in the protocol). 
Table 5. Characteristics of patients with chromosomal aberrations
P Pa at tiie en nt t A Ag ge e S Se ex x D Diia ag gn no os siis s T Tr ra an ns sllo oc ca at tiio on n D D0 0 D D3 30 0 D D9 90 0 D D1 18 80 0 D D2 27 70 0 D D3 36 60 0 S Su ur rv viiv va all
I In niit tiia alls s ( (m mo on nt th hs s) )
O OE E 28 M B-ALL t(1;19) (+) (+) NA - - - 3
Ö ÖÖ Ö 67 M B-ALL t(9;22)-p210 (+) (-) NA NA (+) ND 14
B BÇ Ç 21 F B-ALL t(9;22)-p210 (+) (+) NA (+) ND ND 14
M MÇ Ç 45 F B-ALL t(4;11) (+) (+) (-) (-) (-) (+) 16
T TE E 44 M B-ALL t(9;22)-p190 (+) (-) NA (+) - - 7
NA: Not available (due to technical reasons). ND: Not done (the patient had morphologically active disease). M: Male. F: Female
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P PI I A Ag ge e S Se ex x D Dx x I Ig g/ /T TC CR R    T TS S D D0 0 D D3 30 0 D D9 90 0 D D1 18 80 0 D D2 27 70 0 D D3 36 60 0 M MR R S Su ur rv viiv va all
R Re ea ar rr ra an ng ge em me en nt t ( (m mo on nt th hs s) )
NY 31 F T- No clonal 
ALL rearrangement I 63*
could be detected
RA 19 M T- Vg4-Jg2.3 10-5
ALL Vb7.7-Db1-Jb1.5 10-5 1,E+00 Neg. Neg. Neg. Neg. Neg. L 63
SU 21 M B- No clonal  I 14*
ALL rearrangement
could be detected
HK 56 F B- Vg3-Jg2.3 10-3 1,E+00 NA 8,E-02 NA Neg. Neg. I 49
ALL Intron-Kde
HA 32 F T- No clonal  I 28*
ALL rearrangement
could be detected
GG 22 M B- Vg2-Jg1.3 10-4 1,E+00 2,E-02 Neg. 1,E+02 NA NA H 14
ALL Vd2-Dd3 10-4 1,E+00 2,E-02 2,E-04 1,E+02
ÇÖ 24 F T- Vb12.4-Db1-Jb2.7  MRD monitoring could not be done due to inadequate  I 5*
ALL follow-up material
YD 16 M B- Vd2-Dd3-Ja30 10-4 1,E+00 Neg. Neg. Neg. NA Neg. L 33
ALL Vh3.33-Dh2.2-Jh6
Vh4.4-Dh2.21-Jh5b 10-3
SA 43 F B- Vg2-Jg2.3 10-4 1,E+00 NA NA 2,E-04 NA 2,E-02 H 22
ALL Vh3.7-Dh2.2-Jh6 10-4
NA 17 F B- No clonal  I 37*
ALL rearrangement
could be detected
SA 27 M B- Vg9-Jg2.3
ALL Vd2-Dd3 10-3
Vh3.7-Dh5.5-Jh4b 10-4 MRD monitoring could not be done due to inadequate I 41
Vd2-Dd3-Ja29 follow-up material
Vd2-Dd3-Ja58
AÇ 42 M B- Vk1.17-Kde 10-4 1,E+00 6,E-02 4,E-02 Neg. NA Neg. I 41*
ALL Vh3.23-Dh4.17-Jh4b
Vk2.3-Kde
HA 37 F B- No clonal  I5 *
ALL rearrangement
could be detected
ST 22 M T- No clonal  I 53*
ALL rearrangement
could be detected
ÖA 16 F B- Db2-Jb2.7 10-4 1,E+00 Neg. NA 5,E-04 2,E-06 NA L 35
ALL
AY 41 M T- No clonal  I6
ALL rearrangement
could be detected
P PI I: : Patient initials, M M: : Male, F F: : Female, D Dx x: : Diagnosis, T TS S: : Threshold sensitivity, M MR R: : MRD-based risk group, L L: : Low, I I: : Intermediate, H H: : High, N NA A: : Not available, N Ne eg g. .: : Negative, * Patients
had either no clonal rearrangement or inadequate follow-up
Discussion
Evidence-based data reported over the last years strongly
indicate the importance of MRD monitoring in acute leukemias of
adults and children. To date, there are two primary methods of
MRD monitoring: immunophenotyping and molecular (genetic)
studies. Both of these techniques have been studied 
extensively in adult ALL and were approved as valuable tools for
relapse prediction. Since durable remission and long-term 
survival rates are less satisfying in adult ALL than in childhood
ALL, MRD detection becomes much more important for the 
former. In Turkey, regular MRD monitoring for ALL is not a 
routine procedure except in some individual cases with known
translocations. 
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clinical importance of MRD-based management of ALL but also
to establish the laboratory procedures of molecular MRD 
monitoring for follow-up of patients receiving a standard
chemotherapy. 
Although time-consuming, laborious and costly, MRD 
monitoring is considered to be worthwhile, as it clearly indicates
the relapse before it becomes clinically evident. Several studies
reported that MRD positivity was associated with increased
relapse rates. A greater proportion of these studies dealt with Ph
chromosome-positive ALL patients, confirming that persistence
or reappearance of bcr/abl positivity indicated a higher risk 
of relapse. Concordant results were obtained using 
immunoglobulin heavy chain (IgH)/TCR rearrangement as a
marker for MRD in adult ALL. For example, semi-quantitative IgH
gene analysis in a series of 85 adult precursor B-lineage ALL 
(B-ALL), done by Mortuza et al. [15] during the first 24 months of
treatment, showed that MRD positivity was associated with
increased relapse rates.
Although no statistical evaluation could be done due to our
low patient number, our data are in line with the results of 
recently published studies confirming the evidence that the
molecular MRD status of bone marrow is a strong predictor of
outcome in adults with ALL. All of our patients with bad 
prognostic translocations died within a median of 14 months
despite intensified chemotherapy for high-risk patients. Only
patient MÇ, who became MRD-negative in the 3rd month (D90)
and preserved MRD negativity for about six months, survived
longer. Her disease relapsed soon after MRD was determined
positive. 
In line with the literature, MRD-based low- and 
intermediate-risk patients in our study had a significantly higher
overall survival than high-risk patients (35 and 37 months 
versus 18 months) [20]. The slightly higher survival in the 
intermediate-risk group over the low-risk group (37 months 
versus 35 months) can be explained by the inclusion criteria for
the MRD-based intermediate-risk group. This risk group, by 
definition, included all patients with inconclusive and/or 
technically incomplete MRD monitoring. A significant number of
our intermediate-risk patients would have probably fallen into the
low-risk category if they had had interpretable or technically
available results.
In conclusion, MRD monitoring is progressively becoming a
more important predictive factor in adult ALL patients. As 
reported by others and confirmed by our limited data, there is a
good correlation between MRD status and clinical outcome in
patients receiving chemotherapy. The guidance of MRD 
monitoring will result in MRD-based individualization of treatment
protocols, leading to tailoring of unnecessary consolidations in
some low-risk patients while alerting to the need for 
transplantation in others. 
To keep pace with the evolving molecular biology and 
genetic techniques and current leukemia management 
strategies requiring central MRD monitoring, Turkey has to
develop new policies and the necessary basic services. Having
experienced the difficulties of establishing a “new” system, we
think we have opened a door towards developing a central 
laboratory for MRD follow-up. We hope that our contribution will
bring country-wide interested parties together to work on a
large-scale MRD study in ALL. 
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